


**ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED**

REGD. OFF: 41, 3rd CROSS, V BLOCK, RAJAJINAGAR, BANGALORE - 560 010

**AUDITED FINANCIAL RESULTS FOR YEAR ENDED 30th JUNE 2009**
**SEGMENTWISE REVENUE, RESULTS AND CAPITAL EMPLOYED**

(Rs. In lakhs)

(Rs. In lakhs)

PARTICULARS	Apr- Jun'2009	Apr- Jun'2008	Jul- Jun'2009	Apr- Jun'2008	Quarter ended 30.06.09	Quarter ended 30.06.08	Twelve months ended 30.06.09	Fifteen months ended 30.06.08
	3 months		12 months (Audited)	15 months (Audited)				
1. Sales/Income from Operations	1835.88	1822.49	7913.72	8801.09				
Less: Excise duty	67.61	146.86	441.17	924.52				
Sales (Net)	1768.27	1675.63	7472.55	7876.57				
2. Other Income								
Manufacturing	3.14	5.94	20.29	33.74				
Other	79.63	54.82	174.93	254.36				
3. Total Income (1+2)	1851.04	1736.39	7667.77	8164.67				
4. Total Expenditure								
a. (Increase)/decrease in stock in trade and work in progress	94.94	30.82	(35.74)	145.67				
b. Consumption of raw materials	494.29	769.92	3068.26	3207.27				
c. Purchase of traded goods	224.29	134.90	862.82	803.42				
d. Employee cost	346.10	349.20	1323.36	1629.78				
e. Depreciation	49.51	36.26	183.54	201.17				
f. Other expenditure	634.86	500.36	2212.33	2835.42				
g. Total	1843.99	1821.46	7414.57	8622.73				
5. Interest	56.16	34.38	176.52	303.67				
6. Extraordinary Items	0.00	0.00	0.00	0.00				
7. Profit(+)/Loss(-) from ordinary activities before Tax (3)-(4+5+6)	(49.11)	(119.45)	76.68	(761.73)				
8. Tax Expenses								
- Current	2.50	450.00	9.50	450.00				
- Deferred	(9.73)	(2.72)	32.30	(13.69)				
- Fringe Benefit Tax	0.00	4.01	19.01	27.91				
9. Net Profit(+)/Loss(-) from ordinary activities after Tax (7)-(8)	(41.88)	(570.74)	15.87	(1225.95)				
10. Extraordinary Items (net of Tax expenses)	0.00	1972.78	0.00	1972.78				
11. Net Profit/(Loss) for the period	(41.88)	1402.04	15.87	746.83				
12. Paid up equity share capital	116.25	116.25	116.25	116.25				
13. Reserves excluding revaluation reserve			1069.58	1046.02				
14. Earning per shares								
a) Basic and Diluted before extraordinary items	(3.80)	(49.10)	1.36	(86.75)				
b) Basic and Diluted after extraordinary items	(3.60)	120.61	1.36	64.24				
15. Public Share holding								
- No. of shares (Face value of Rs. 10/- each)	548275	551025	548275	551025				
- Percentage of holding	47.16	47.40	47.16	47.40				
16. Promoters and Promoter Group Shareholding								
a) Pledged/Encumbered								
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	0.00	0.00	0.00	0.00				
- Percentage of shares (as a % of the total capital of the Company)	0.00	0.00	0.00	0.00				
b) Non-encumbered								
Number of Shares	614225	611475	614225	611475				
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100	100	100	100				
- Percentage of shares (as a % of the total capital of the Company)	52.84	52.60	52.84	52.60				
1. Segment Revenue								
a. Pharma	1755.10	1639.92	7210.55	7430.45				
b. Furnishing	95.94	96.47	456.72	733.94				
c. Unallocated	0.00	0.00	0.50	0.28				
Total	1851.04	1736.39	7667.77	8164.67				
Less: Inter segment Revenue	0.00	4.14	21.61	101.40				
Net Sales/Income from operations	1851.04	1732.25	7646.16	8063.27				
2. Segment Results (Profit (+)/Loss (-) before tax and interest from each segment)								
a. Pharma	7.49	1934.72	336.80	1685.68				
b. Furnishing	0.63	(43.87)	(73.95)	(159.78)				
c. Unallocated	0.00	0.00	0.00	0.00				
Total	8.12	1890.85	262.85	1525.90				
Less:								
i) Interest (net)	56.16	34.38	176.52	303.67				
ii) Other Unallocable expenditure net of unallocable income	1.07	3.14	9.65	11.18				
Total Profit/(Loss) before tax	(49.11)	1853.33	76.68	1211.05				
3. Capital Employed (Segment Assets - Segment Liabilities)								
a. Pharma	2125.16	1923.57	2125.16	1923.57				
b. Furnishing	557.13	607.13	557.13	607.13				
c. Unallocated	54.01	8.14	54.01	8.14				
Total	2736.30	2538.84	2736.30	2538.84				